 David Mathes
Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 16 | 2022 | 49 | 6.080 |
Why?
| | Surgical Flaps | 8 | 2018 | 123 | 3.020 |
Why?
| | Reconstructive Surgical Procedures | 10 | 2014 | 261 | 2.560 |
Why?
| | Perforator Flap | 5 | 2022 | 13 | 2.410 |
Why?
| | Transplantation Tolerance | 8 | 2016 | 32 | 2.290 |
Why?
| | Skin Transplantation | 9 | 2018 | 60 | 2.240 |
Why?
| | Microsurgery | 8 | 2020 | 51 | 1.980 |
Why?
| | Graft Survival | 14 | 2020 | 394 | 1.960 |
Why?
| | Composite Tissue Allografts | 4 | 2016 | 5 | 1.960 |
Why?
| | Vascularized Composite Allotransplantation | 3 | 2020 | 9 | 1.950 |
Why?
| | Facial Transplantation | 4 | 2014 | 7 | 1.840 |
Why?
| | Graft Rejection | 11 | 2016 | 572 | 1.750 |
Why?
| | Hand Transplantation | 5 | 2011 | 8 | 1.740 |
Why?
| | Epigastric Arteries | 7 | 2022 | 10 | 1.670 |
Why?
| | Surgery, Plastic | 4 | 2019 | 23 | 1.670 |
Why?
| | Transplantation Chimera | 6 | 2014 | 59 | 1.400 |
Why?
| | Bone Marrow Transplantation | 6 | 2014 | 293 | 1.350 |
Why?
| | Transplantation, Homologous | 14 | 2016 | 490 | 1.240 |
Why?
| | Rectus Abdominis | 3 | 2021 | 8 | 1.230 |
Why?
| | Immune Tolerance | 7 | 2014 | 362 | 1.210 |
Why?
| | Angiography | 4 | 2013 | 158 | 1.090 |
Why?
| | Preoperative Care | 5 | 2012 | 339 | 1.000 |
Why?
| | Vascular Surgical Procedures | 2 | 2019 | 232 | 0.980 |
Why?
| | Fat Necrosis | 1 | 2021 | 6 | 0.940 |
Why?
| | Transplant Donor Site | 1 | 2021 | 3 | 0.940 |
Why?
| | Surgical Wound Dehiscence | 1 | 2021 | 20 | 0.930 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 20 | 0.930 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2016 | 575 | 0.910 |
Why?
| | Kidney Transplantation | 5 | 2012 | 382 | 0.870 |
Why?
| | Abdominal Wall | 2 | 2010 | 23 | 0.810 |
Why?
| | Tissue Transplantation | 3 | 2012 | 15 | 0.750 |
Why?
| | Free Tissue Flaps | 2 | 2020 | 29 | 0.730 |
Why?
| | Nipples | 1 | 2018 | 8 | 0.730 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2016 | 19 | 0.670 |
Why?
| | Tomography, X-Ray Computed | 3 | 2012 | 2380 | 0.650 |
Why?
| | Tissue and Organ Harvesting | 2 | 2014 | 62 | 0.640 |
Why?
| | Patient Safety | 1 | 2019 | 309 | 0.610 |
Why?
| | Bone Marrow Cells | 1 | 2016 | 330 | 0.590 |
Why?
| | Myocutaneous Flap | 1 | 2014 | 5 | 0.570 |
Why?
| | Groin | 1 | 2014 | 11 | 0.570 |
Why?
| | Perineum | 1 | 2014 | 30 | 0.560 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 35 | 0.560 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 75 | 0.540 |
Why?
| | Pelvis | 1 | 2014 | 77 | 0.530 |
Why?
| | Practice Patterns, Physicians' | 2 | 2020 | 1214 | 0.520 |
Why?
| | Dogs | 5 | 2016 | 472 | 0.500 |
Why?
| | Breast | 2 | 2011 | 142 | 0.500 |
Why?
| | Face | 2 | 2013 | 177 | 0.470 |
Why?
| | Swine, Miniature | 7 | 2014 | 77 | 0.470 |
Why?
| | Retrospective Studies | 14 | 2022 | 11340 | 0.460 |
Why?
| | Pressure Ulcer | 1 | 2011 | 25 | 0.460 |
Why?
| | Communications Media | 1 | 2011 | 5 | 0.460 |
Why?
| | Surgical Wound Infection | 3 | 2018 | 224 | 0.450 |
Why?
| | Attitude of Health Personnel | 2 | 2009 | 997 | 0.450 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 97 | 0.440 |
Why?
| | Models, Animal | 3 | 2012 | 394 | 0.430 |
Why?
| | Diphtheria Toxin | 2 | 2021 | 69 | 0.420 |
Why?
| | Swine | 9 | 2014 | 716 | 0.420 |
Why?
| | Humans | 42 | 2022 | 113846 | 0.420 |
Why?
| | Osteomyelitis | 1 | 2011 | 105 | 0.410 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2010 | 28 | 0.410 |
Why?
| | Coitus | 1 | 2010 | 31 | 0.410 |
Why?
| | Ultrasonography, Doppler | 1 | 2010 | 113 | 0.410 |
Why?
| | Amputation, Traumatic | 1 | 2009 | 12 | 0.390 |
Why?
| | Facial Injuries | 1 | 2009 | 18 | 0.390 |
Why?
| | Arteries | 2 | 2013 | 238 | 0.390 |
Why?
| | Traumatology | 1 | 2009 | 26 | 0.380 |
Why?
| | Internet | 2 | 2011 | 633 | 0.380 |
Why?
| | Hand Injuries | 1 | 2009 | 30 | 0.380 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 220 | 0.360 |
Why?
| | Vagina | 1 | 2010 | 163 | 0.360 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2008 | 20 | 0.360 |
Why?
| | Thigh | 1 | 2008 | 53 | 0.360 |
Why?
| | Middle Aged | 15 | 2021 | 28753 | 0.340 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 89 | 0.340 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4906 | 0.340 |
Why?
| | Orthopedics | 1 | 2009 | 143 | 0.330 |
Why?
| | Acellular Dermis | 2 | 2018 | 10 | 0.330 |
Why?
| | Female | 23 | 2021 | 63035 | 0.320 |
Why?
| | Wounds and Injuries | 2 | 2012 | 911 | 0.310 |
Why?
| | Patient Satisfaction | 1 | 2010 | 602 | 0.300 |
Why?
| | Histocompatibility | 3 | 2014 | 33 | 0.300 |
Why?
| | Anastomosis, Surgical | 3 | 2020 | 122 | 0.290 |
Why?
| | Transplantation Conditioning | 3 | 2016 | 188 | 0.280 |
Why?
| | Societies, Medical | 1 | 2009 | 768 | 0.280 |
Why?
| | Breast Neoplasms | 3 | 2017 | 1909 | 0.280 |
Why?
| | Immunosuppressive Agents | 6 | 2014 | 676 | 0.270 |
Why?
| | Fetus | 2 | 2005 | 680 | 0.270 |
Why?
| | Hindlimb | 2 | 2003 | 138 | 0.260 |
Why?
| | Animals | 17 | 2021 | 35394 | 0.250 |
Why?
| | Treatment Outcome | 10 | 2019 | 9002 | 0.240 |
Why?
| | Extremities | 2 | 2002 | 117 | 0.240 |
Why?
| | Weight Loss | 1 | 2008 | 694 | 0.240 |
Why?
| | Cyclosporine | 3 | 2016 | 186 | 0.220 |
Why?
| | Computed Tomography Angiography | 1 | 2021 | 67 | 0.220 |
Why?
| | Adult | 10 | 2021 | 31979 | 0.210 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 162 | 0.210 |
Why?
| | Body Mass Index | 1 | 2008 | 2098 | 0.210 |
Why?
| | Immunotoxins | 1 | 2020 | 29 | 0.210 |
Why?
| | Postoperative Complications | 4 | 2018 | 2116 | 0.210 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2020 | 36 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 347 | 0.210 |
Why?
| | Bone Transplantation | 1 | 2001 | 109 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3049 | 0.200 |
Why?
| | Skin Neoplasms | 2 | 2020 | 737 | 0.200 |
Why?
| | Flow Cytometry | 4 | 2020 | 1184 | 0.200 |
Why?
| | Keloid | 1 | 2019 | 6 | 0.200 |
Why?
| | Abdomen | 2 | 2010 | 127 | 0.190 |
Why?
| | Dermis | 1 | 2019 | 34 | 0.190 |
Why?
| | Antigens | 2 | 2016 | 351 | 0.190 |
Why?
| | Time Factors | 6 | 2014 | 7060 | 0.190 |
Why?
| | Interleukin-2 | 1 | 2020 | 415 | 0.190 |
Why?
| | Fluorouracil | 1 | 2019 | 139 | 0.190 |
Why?
| | Reoperation | 2 | 2017 | 538 | 0.180 |
Why?
| | Tattooing | 1 | 2018 | 12 | 0.180 |
Why?
| | Chimera | 2 | 2011 | 60 | 0.170 |
Why?
| | Graft vs Host Disease | 2 | 2016 | 229 | 0.170 |
Why?
| | Data Collection | 2 | 2011 | 672 | 0.170 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 95 | 0.160 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2016 | 76 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 77 | 0.160 |
Why?
| | Hernia, Ventral | 1 | 2016 | 21 | 0.160 |
Why?
| | Bupivacaine | 1 | 2016 | 35 | 0.160 |
Why?
| | Herniorrhaphy | 1 | 2016 | 31 | 0.160 |
Why?
| | Surgical Mesh | 1 | 2016 | 34 | 0.160 |
Why?
| | Length of Stay | 1 | 2021 | 1062 | 0.160 |
Why?
| | Prospective Studies | 3 | 2021 | 6250 | 0.160 |
Why?
| | Imaging, Three-Dimensional | 2 | 2010 | 557 | 0.150 |
Why?
| | Leukocytes | 1 | 2016 | 301 | 0.150 |
Why?
| | Whole-Body Irradiation | 2 | 2012 | 79 | 0.150 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2014 | 55 | 0.140 |
Why?
| | Cadaver | 2 | 2010 | 271 | 0.140 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 25 | 0.140 |
Why?
| | United States | 4 | 2020 | 12329 | 0.140 |
Why?
| | Breast Implantation | 1 | 2014 | 4 | 0.140 |
Why?
| | Pain, Postoperative | 1 | 2016 | 193 | 0.140 |
Why?
| | False Negative Reactions | 1 | 2014 | 70 | 0.140 |
Why?
| | CD3 Complex | 1 | 2014 | 97 | 0.140 |
Why?
| | Patient Selection | 2 | 2008 | 694 | 0.140 |
Why?
| | Allografts | 1 | 2014 | 106 | 0.140 |
Why?
| | Dissection | 1 | 2014 | 53 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2014 | 138 | 0.130 |
Why?
| | Temporal Arteries | 1 | 2014 | 43 | 0.130 |
Why?
| | Histocompatibility Antigens | 1 | 2014 | 101 | 0.130 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 4625 | 0.130 |
Why?
| | Random Allocation | 1 | 2014 | 402 | 0.130 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 181 | 0.130 |
Why?
| | Prosthesis Failure | 1 | 2014 | 118 | 0.130 |
Why?
| | Postoperative Period | 1 | 2014 | 290 | 0.130 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 29 | 0.130 |
Why?
| | Risk Assessment | 2 | 2014 | 3147 | 0.130 |
Why?
| | Pain Management | 1 | 2016 | 306 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2014 | 157 | 0.120 |
Why?
| | Health Care Costs | 1 | 2016 | 395 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2014 | 445 | 0.120 |
Why?
| | Paternalism | 1 | 2011 | 5 | 0.120 |
Why?
| | Indocyanine Green | 1 | 2011 | 13 | 0.120 |
Why?
| | Beneficence | 1 | 2011 | 18 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 277 | 0.120 |
Why?
| | Marketing of Health Services | 1 | 2011 | 18 | 0.110 |
Why?
| | Hematopoiesis | 1 | 2012 | 182 | 0.110 |
Why?
| | Collagen | 1 | 2014 | 449 | 0.110 |
Why?
| | Intraoperative Care | 1 | 2011 | 52 | 0.110 |
Why?
| | Personal Autonomy | 1 | 2011 | 44 | 0.110 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1423 | 0.110 |
Why?
| | Ethics, Medical | 1 | 2011 | 86 | 0.110 |
Why?
| | Professional Practice | 1 | 2011 | 65 | 0.110 |
Why?
| | Treatment Failure | 1 | 2012 | 329 | 0.110 |
Why?
| | Informed Consent | 1 | 2011 | 156 | 0.110 |
Why?
| | Suture Techniques | 1 | 2011 | 126 | 0.110 |
Why?
| | Disease Models, Animal | 3 | 2014 | 3910 | 0.100 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2010 | 36 | 0.100 |
Why?
| | Radiography, Abdominal | 1 | 2010 | 35 | 0.100 |
Why?
| | Neovascularization, Physiologic | 1 | 2011 | 201 | 0.100 |
Why?
| | Organ Transplantation | 1 | 2011 | 142 | 0.100 |
Why?
| | Transplantation, Autologous | 1 | 2010 | 195 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1930 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1529 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2905 | 0.090 |
Why?
| | North America | 1 | 2009 | 274 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 788 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 694 | 0.080 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 271 | 0.080 |
Why?
| | Head and Neck Neoplasms | 1 | 2012 | 400 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2009 | 580 | 0.080 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 728 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 789 | 0.080 |
Why?
| | Burns | 1 | 2009 | 200 | 0.080 |
Why?
| | Male | 7 | 2016 | 60993 | 0.080 |
Why?
| | Cytokines | 1 | 2014 | 1981 | 0.080 |
Why?
| | Linear Models | 1 | 2008 | 909 | 0.080 |
Why?
| | Aged | 5 | 2017 | 20109 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 2005 | 230 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2008 | 1517 | 0.070 |
Why?
| | Melanoma | 1 | 2012 | 719 | 0.070 |
Why?
| | Tissue Donors | 1 | 2005 | 301 | 0.070 |
Why?
| | Biomarkers | 1 | 2014 | 3501 | 0.060 |
Why?
| | Physicians | 1 | 2011 | 711 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1268 | 0.060 |
Why?
| | Pregnancy | 1 | 2014 | 5290 | 0.060 |
Why?
| | Umbilicus | 1 | 2022 | 16 | 0.060 |
Why?
| | Transplantation Immunology | 1 | 2002 | 40 | 0.060 |
Why?
| | Peripheral Nerves | 1 | 2002 | 67 | 0.060 |
Why?
| | Cicatrix | 1 | 2022 | 61 | 0.060 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 70 | 0.060 |
Why?
| | Musculoskeletal System | 1 | 2001 | 35 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1599 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2001 | 138 | 0.050 |
Why?
| | Quality of Life | 1 | 2011 | 2136 | 0.050 |
Why?
| | Receptors, CCR4 | 1 | 2020 | 17 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 88 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 59 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 363 | 0.050 |
Why?
| | Forelimb | 1 | 1999 | 27 | 0.050 |
Why?
| | Histocompatibility Testing | 1 | 2000 | 134 | 0.050 |
Why?
| | Injections, Intralesional | 1 | 2019 | 34 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 564 | 0.050 |
Why?
| | Lymphocytes | 1 | 2001 | 392 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2001 | 307 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2019 | 133 | 0.050 |
Why?
| | Tacrolimus | 1 | 1999 | 143 | 0.050 |
Why?
| | Margins of Excision | 1 | 2017 | 31 | 0.040 |
Why?
| | Skin | 1 | 2003 | 702 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 59 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2019 | 335 | 0.040 |
Why?
| | Narcotics | 1 | 2016 | 62 | 0.040 |
Why?
| | Cost Savings | 1 | 2016 | 83 | 0.040 |
Why?
| | Recurrence | 1 | 2019 | 967 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1458 | 0.040 |
Why?
| | Anesthetics, Local | 1 | 2016 | 90 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 400 | 0.040 |
Why?
| | Nerve Block | 1 | 2016 | 66 | 0.040 |
Why?
| | Consensus | 1 | 2017 | 427 | 0.040 |
Why?
| | Biopsy | 1 | 2019 | 1065 | 0.040 |
Why?
| | Tissue Expansion Devices | 1 | 2014 | 3 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 307 | 0.040 |
Why?
| | Tissue Expansion | 1 | 2014 | 7 | 0.040 |
Why?
| | Breast Implants | 1 | 2014 | 10 | 0.030 |
Why?
| | Cellulitis | 1 | 2014 | 42 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 858 | 0.030 |
Why?
| | Mastectomy | 1 | 2014 | 110 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2014 | 133 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 693 | 0.030 |
Why?
| | Mice | 2 | 2021 | 15641 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 537 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 2936 | 0.030 |
Why?
| | Leukocyte Transfusion | 1 | 2012 | 2 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 528 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2000 | 1302 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 9050 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1640 | 0.030 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 182 | 0.030 |
Why?
| | Wound Healing | 1 | 2014 | 331 | 0.030 |
Why?
| | Fluorescence | 1 | 2011 | 160 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 2053 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2013 | 6796 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2013 | 739 | 0.030 |
Why?
| | Transcription Factors | 1 | 2019 | 1643 | 0.030 |
Why?
| | Equipment Design | 1 | 2011 | 531 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1601 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2470 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4581 | 0.020 |
Why?
| | Young Adult | 2 | 2013 | 10971 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 969 | 0.020 |
Why?
| | Smoking | 1 | 2014 | 1632 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2004 | 212 | 0.020 |
Why?
| | Antigens, Surface | 1 | 2001 | 165 | 0.010 |
Why?
| | Obesity | 1 | 2014 | 2627 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2004 | 1846 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4429 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 18736 | 0.010 |
Why?
|
|
Mathes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|